Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Suven Life Sciences
Small Cap•141 Employees•IPO 1995
Current Price
₹137.61
0.89 (0.65%)Updated
Today's Range
135.04
₹137.61
141.29
52 Week Range
52W Low₹113.00
52W High₹299.99
₹137.61
Downside21.78%
Upside118.00%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹3,449.65 Cr
Market Cap
Total market value of companyP/E Ratio
-
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
16.52
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹-9.64
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-61.98%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
-87.00%
ROCE
Return on Capital Employed. >15% is goodNet Margin
-3614.11%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-52.85%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
85.20%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-83.70%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
-
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹5.04
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
67.40%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Strong promoter holding of 67.36% indicates significant insider confidence.
- •Zero debt-to-equity ratio (0.00) provides substantial financial flexibility.
Weaknesses
5 points- •Persistent net losses, with latest quarter showing -51.5 Cr loss.
- •Deeply negative ROE (-87.20%) and ROCE (-87.00%) indicate severe inefficiency.
Opportunities
5 points- •Burgeoning Healthcare Research Analytics & Technology sector offers substantial growth opportunities.
- •Significant quarterly sales growth (85.20%) could signal a revenue turnaround.
Threats
5 points- •Intense competition from profitable peers given deeply negative ROCE (-87.00%).
- •Significant regulatory risks in healthcare research impact operations and compliance.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹153.42 | +₹15.81 | +11.49% |
| R3 | ₹147.17 | +₹9.56 | +6.95% |
| R2 | ₹144.23 | +₹6.62 | +4.81% |
| R1 | ₹140.92 | +₹3.31 | +2.41% |
| PIVOT | ₹137.98 | 0.37 | 0.27% |
| CURRENT | ₹137.61 | - | - |
| S1 | ₹122.17 | -₹15.44 | -11.22% |
| S2 | ₹128.42 | -₹9.19 | -6.68% |
| S3 | ₹131.73 | -₹5.88 | -4.27% |
| S4 | ₹134.67 | -₹2.94 | -2.14% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+76.2% vs avg
4.32L
(13 Mar 2026)Delivery %+7.1% vs avg
55.3%
(13 Mar 2026)Avg Volume (20D)20-day average
2.45L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
48.2%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Divis Laboratories Ltd
1.64L ₹ Cr
Best Profit Growth
Sai Life Sciences Ltd
548.00 %
Highest Dividend Yield
Windlas Biotech Ltd
1.29 %
Peer Comparison
| Company Name |
|---|
 Akums Drugs & Pharmaceuticals Ltd |
 Borosil Scientific Ltd |
 Brooks Laboratories Ltd |
 Dishman Carbogen Amcis Ltd |
 Divis Laboratories Ltd |
 |
 Indegene Ltd |
 Innova Captab Ltd |
 OneSource Specialty Pharma Ltd |
 Sai Life Sciences Ltd |
 Syngene International Ltd |
 Tarsons Products Ltd |
 Vimta Labs Ltd |
 Windlas Biotech Ltd |
About
Suven Life Sciences Ltd
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company concentrating on the research, development, and commercialization of novel therapeutics to treat neurodegenerative disorders. Their operations span across India, the United States, Europe, and other international markets. The company's core business is focused on drug discovery and development, specifically targeting new chemical entities to combat central nervous system (CNS) diseases.
Suven's pipeline includes several promising product candidates at various stages of development. Masupirdine (SUVN-502) is being investigated for Alzheimer's disease and associated neuropsychiatric symptoms. Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist, is being explored for the treatment of sleep and cognitive disorders. Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist, is in development for depressive disorders.
Further enriching their portfolio, Suven is actively developing Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist aimed at treating cognitive disorders. Additionally, the company has several other compounds under investigation, including SUVN-I6107 and SUVN-M8036, targeting cognitive and psychiatric disorders respectively. SUVN-D1044 is being developed for gastrointestinal disorders, showcasing the company's exploration beyond the CNS therapeutic area.
Established in 1989 and headquartered in Hyderabad, India, Suven Life Sciences Limited has undergone a name change from Suven Pharmaceuticals Pvt. Ltd. in 2003. The company's history reflects a commitment to innovation in the field of neurodegenerative disease treatment. Currently, it operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
COMPANY FACTS - SUVEN
Registered Address
SDE Serene Chambers 6th Floor, Road No. 5 Avenue 7, Banjara Hills
Hyderabad
TELANGANA
IN
Tel: 914023541142
Website:https://www.suven.com/
Investor Relations:http://www.suven.com/annual-reports.html
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Life Sciences Tools & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 141
IPO Date: 06/03/1995
MANAGEMENT - SUVEN
Shri. Venkateswarlu Jasti
Executive Chairman of the Board, Managing Director
Mr. M. Mohan Kumar
Chief Financial Officer
Mr. Shrenik Soni
Chief Compliance Officer, Company Secretary
Smt. Sudha Jasti
Wholetime Director
Prof. Dr. Syed Hasnain
Non-Executive Director
Shri. Santanu Mukherjee
Independent Non-Executive Director
Smt. J.A.S Padmaja
Non-Executive Independent Director
Mr. Vajja Rao
Additional Non-Executive Independent Director
Investor Questions Answered
Suven Life Sciences Ltd (SUVEN) Stock FAQs
Get answers to the most common questions about Suven Life Sciences Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Suven Life Sciences Ltd (SUVEN) is ₹137.61. Today, the stock has gained by ₹0.89 (0.65%), trading in a range of ₹135.04 to ₹141.29. The stock opened at ₹137.4 with a trading volume of 4,31,771 shares.
Suven Life Sciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,449.65 crores, P/E ratio of 0.00, ROE of -61.98%, and ROCE of -87.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Suven Life Sciences Ltd (SUVEN) is ₹299.99, while the 52-week low is ₹113. Currently trading at ₹137.61, the stock is 13.2% away from its 52-week low and 54.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Suven Life Sciences Ltd stock at ₹137.61 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a gain of 0.65%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Suven Life Sciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹137.61, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Suven Life Sciences Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -61.98%, ROCE: -87.00%, Dividend Yield: 0.00%, EPS: ₹-9.64, Book Value: ₹5.04, Debt-to-Equity: 0.00, and Current Ratio: N/A. The company's market cap stands at ₹3,449.65 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Suven Life Sciences Ltd stock opened at ₹137.4 and is currently trading at ₹137.61, showing a gain of ₹0.89 (0.65%). The intraday high is ₹141.29 and low is ₹135.04. The trading volume stands at 4,31,771 shares, indicating moderate market participation today.
Suven Life Sciences Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-9.64, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Suven Life Sciences Ltd has a market capitalization of ₹3,449.65 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹137.61) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Suven Life Sciences Ltd has a book value of ₹5.04 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹137.61, which is 2630.4% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Suven Life Sciences Ltd has a Return on Equity (ROE) of -61.98% and Return on Capital Employed (ROCE) of -87.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Suven Life Sciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Suven Life Sciences Ltd has a debt-to-equity ratio of 0.00, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Suven Life Sciences Ltd has an Earnings Per Share (EPS) of ₹-9.64, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹137.61 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Suven Life Sciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Suven Life Sciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Suven Life Sciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (-61.98%), debt-to-equity (0.00), and growth rates. 2) Technical Analysis - Check 52-week range (₹113.00 - ₹299.99), moving averages, and chart patterns. 3) Valuation - Compare current price (₹137.61) with book value (₹5.04) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Suven Life Sciences Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹137.61 is 13661x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Suven Life Sciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹113.00 - ₹299.99). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.00 indicates leverage. 4) Liquidity Risk - Based on trading volume of 4,31,771 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Suven Life Sciences Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of -61.98%, market cap of ₹3,449.65 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.00), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Suven Life Sciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹137.61, with a 52-week range of ₹113.00 to ₹299.99. Based on fundamentals like P/E (0.00), ROE (-61.98%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Suven Life Sciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹137.61. 2) Fundamental Deterioration - Declining ROE (currently -61.98%), increasing debt (D/E: 0.00), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Suven Life Sciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu